INTRODUCTION
Oral anticoagulation is essential for the prevention and treatment of embolism and thrombosis. Only in the United States, over six million people use oral anticoagulant medication (OACs), which could be related to higher risk of bleeding and could also echo in morbidymortality of this group 1 .
The incidence of diseases that require OACs have been progressively increasing and this is directly linked to the aging of the population. Atrial fibrillation (AF), the most prevalent arrhythmia in the world, presented an enhance of 13% regarding incidence in the last two decades, and age is a risk factor not only for the development of AF but also for the risk of cardio thrombolytic events. Cerebral Vascular Accident (CVA)
is the main complication of FA and it is related to this arrhythmia in 20% of the cases 2. Direct Oral Anticoagulants (DOACs), represented by the direct suppressants of Xa factor (rivaroxaban, edoxaban and apixaban), and thrombin direct suppressant (dabigatran) are alternatives to the vitamin K antagonists (VKAs) for the profilaxys and treatment of thrombolytic events, greatly in part related to AF and present a series of clinical advantages when compared to VKAs, such as higher anticoagulant stability and less risk not only for intracranial hemorrhage but also bleeding 5 .
Regarding hemorrhage complications, due to the short half-life of these medications, in most cases only the suspension, associated to clinical support actions, may be enough to stop the bleeding. The usage of prothrombic complex 4 
DEVELOPMENT
Homeostasis is a normal physiological answer from the body that prevents significant blood loss after vascular damage. Coagulation cascade is a complex series of reactions that guarantees the occurrence of homeostasis ( Fig. 1) .
Anticoagulant system, which works in parallel to the fibrinolytic system, guarantees that the formation of the thrombus is a controlled and balanced procedure, allowing the degradation of already formed thrombus.
DOACs are divided into direct inhibitors of thrombin or direct inhibitors of Xa factor, and their characteristics are presented in Table 1 .
Exetilate dabigatran is an oral pro-pharmaceutical that is converted in the liver into dabigatran, a direct, reversible, competitive inhibitor of thrombin 5 The direct inhibitors of Xa factor (rivaroxaban, apixaban and edoxaban) directly linked themselves to the active sites of X factor in the circulation and, linked to the clot, block the interaction with its substrate. They are metabolized by the kidneys (25-35%) and liver (up to 75%) and patients with hepatic insufficiency may present this drug accumulation, but in spite of that, these medications do not seem to be toxic to the liver 8 .
Rivaroxaban is a direct inhibitor, reversible and competitive of the Xa factor, orally administrated.
It should not be use in patients with clearance <15 mL/min, as well as in patients with important liver illness (Child-Pugh B and C with coagulopathy) 9 .
This medication has not been tested in people under 18 years of age 10 .
Rivaroxaban interacts with CYP-3A4 and protein P suppressant drugs (such as ketoconazol, itraconazol, voriconazol, posaconazol and ritonavir) and its concomitant use with these drugs is not recommended 11 .
It is not necessary to perform tests to monitor the coagulation during the treatment with rivaroxaban, except in patients that present bleeding, suspect of medication intoxication or need of emergency surgery 13 .
Apixaban is a direct inhibitor, reversible and competitive of Xa factor, orally administrated, needing adjust of the dose according to the creatinine clearance.
It is also recommended to reduce its dose in patients that use CYP-3A4 and protein P inhibitors 14 .
Edoxaban is a direct inhibitor of Xa factor, selective and reversible 15, 16 . Around 73% of the drug of the dose is eliminated unaltered in urine and faeces 17, 18. The recommended dose for the prevention of Cerebral Vascular Accident in patients with AF is of 60 mg once a day, reducing to 30 mg once a day in patients with creatinine clearance between 15-50 mL/min, weight <60kg or concomitant use of any protein P inhibitor (for ex., verapamil, quinidin, eritromicin and ketoconazol) 19 .
This medication is not recommended for patients with terminal kidney failure, creatinine clearance ,15 mL/min or under hemodialysis.
The incidence of bleeding is 2-3% a year higher in patients using DOACs, being the incidence of CVA 1-0.5% 21 .
DISCUSSION
Hemorrhage management related to the use of DOACs varies according to the gravity of the case. Light hemorrhages may be resolved only with the temporary suspension of the drug and, in the most severe cases, fluid reposition may be needed, as well as hemodynamic support, mechanical compression, surgical hemosthasis, and the use of blood derivatives. If all those measurements were not enough, one must use pro-coagulants, such as the prothrombic complex 21 . intervention, the reserve of the anticoagulant activity may be needed, using DOACs reverse agents 21 . Their indications and characteristics are presented in Table 2 and Table 3 . 
Clinical Measurements
In case of greater bleeding, which occurs in critical location in association with hemodynamic instability or fall of ± 2 g/dL of hemoglobine, DOACs must be suspended, being their specific reverse agents indicated, as well as volume replacement and local hemostasis 22 .
In c ase of exter nal bleeding, loc al control measurements must be performed, preferentially with criastalloides (0.9% saline, Ringer or Lactate), aiming the volemic restauration and hemodynamic stability.
Hypothermia as well as acidosis must be corrected and, in case of symptomatic anemia and/or active bleeding, red blood cells must be transfused, in order to maintain hemoglobin at ± 7 g/dL in general patients and at ± 8 g/dL in coronary patients 23. Plaquets transfusion must be performed if there is less than 50.000 24 Ganem IRA, Martins LCB, Tomé CEM Antifibronilitc agents may be indicated to patients with greater bleeding caused by either Xa inibitors or dabigatran. Activated VII factor, fresh frozen plasma or cryoprecipitate must be avoided due to the lack of studies showing benefits and the associated high risks (for ex., transfusional reaction, volume overload) 21 . 
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